OPN-2853

Poster

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF
Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

  • AUTHORS Duska, et al
  • Programs OPN-2853
https://ascopubs.org/doi/abs/10.1200/PO.23.00235
Poster

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

  • AUTHORS Swisher, et al
  • Programs OPN-2853
Download PDF
Publication

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

https://doi.org/10.3389/fonc.2021.760789
Poster

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

  • AUTHORS Gordon, et al
  • Programs OPN-2853
Download PDF
Poster

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Download PDF
Publication

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

https://doi.org/10.1182/bloodadvances.2020002231
Poster

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • AUTHORS Pemmaraju, et al
  • Programs OPN-2853
Download PDF
Poster

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

  • AUTHORS Patnaik, et al
  • Programs OPN-2853
Download PDF